Advertisement

hautnah dermatologie

, Volume 34, Issue 5, pp 44–51 | Cite as

Neuroendokrines Karzinom der Haut

Merkelzellkarzinom: selten, aber aggressiv

  • Wiebke K. Ludwig-Peitsch
  • Elvira Ruppel
  • Axel Zahn
Zertifizierte Fortbildung
  • 21 Downloads

Zusammenfassung

Das Merkelzellkarzinom ist ein seltenes, aggressiv verlaufendes neuroendokrines Karzinom der Haut. In der Ära der Chemotherapie war die Prognose bei Fernmetastasierung nahezu infaust — mit Einführung der Immuncheckpointinhibitoren wurde das Spektrum der Therapieoptionen wesentlich erweitert.

Literatur

  1. 1.
    Fitzgerald TL et al. Dramatic Increase in the Incidence and Mortality from Merkel Cell Carcinoma in the United States. Am Surg 2015; 81: 802–6PubMedPubMedCentralGoogle Scholar
  2. 2.
    Schadendorf D et al. Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. Eur J Cancer 2017; 71: 53–69CrossRefGoogle Scholar
  3. 3.
    Coggshall K et al. Merkel cell carcinoma: An update and review: Pathogenesis, diagnosis, and staging. J Am Acad Dermatol 2018; 78: 433–42CrossRefGoogle Scholar
  4. 4.
    Feng H et al. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008; 319: 1096–100CrossRefGoogle Scholar
  5. 5.
    Chang Y, Moore PS. Merkel cell carcinoma: a virus-induced human cancer. Annu Rev Pathol 2012; 7: 123–44CrossRefGoogle Scholar
  6. 6.
    Becker JC et al. S2k Kurzleitlinie — MCC. J Dtsch Dermatol Ges 2013; 11 (Suppl 3): 31–8CrossRefGoogle Scholar
  7. 7.
    Harms KL et al. Analysis of Prognostic Factors from 9387 Merkel Cell Carcinoma Cases Forms the Basis for the New 8th Edition AJCC Staging System. Ann Surg Oncol 2016; 23: 3564–71CrossRefGoogle Scholar
  8. 8.
    Samimi M et al. Prognostic value of antibodies to Merkel cell polyomavirus T antigens and VP1 protein in patients with Merkel cell carcinoma. Br J Dermatol 2016; 174: 813–22CrossRefGoogle Scholar
  9. 9.
    Bhatia S et al. Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases from the National Cancer Data Base. J Natl Cancer Inst 2016; 108Google Scholar
  10. 10.
    Tello TL et al. Merkel cell carcinoma: An update and review: Current and future therapy. J Am Acad Dermatol 2018; 78: 445–54CrossRefGoogle Scholar
  11. 11.
    Kaufman HL et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 2016; 17: 1374–85CrossRefGoogle Scholar
  12. 12.
    Kaufman HL et al. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer 2018; 6: 7CrossRefGoogle Scholar
  13. 13.
    D’Angelo SP et al. Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial. JAMA Oncol 2018; https://doi.org/10.1001/jamaoncol.2018.0077CrossRefGoogle Scholar
  14. 14.
    Nghiem PT et al. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med 2016; 374: 2542–52CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  • Wiebke K. Ludwig-Peitsch
    • 1
  • Elvira Ruppel
    • 1
  • Axel Zahn
    • 1
  1. 1.Klinik für Dermatologie und PhlebologieVivantes Klinikum im FriedrichshainBerlinDeutschland

Personalised recommendations